barrier
inde
mani
neuropsychiatr
drug
design
high
clogp
increas
central
nervou
system
penetr
neg
clogp
valu
bisphosphon
antiosteoporot
drug
alendron
indic
compound
hydrophil
pka
refer
acid
dissoci
constant
valu
greater
mean
compound
basic
valu
less
mean
acid
cad
pka
weak
base
molecularli
compar
sever
clinic
import
cad
includ
chloroquin
fda
approv
cad
sertralin
fluoxetin
nortriptylin
amiodaron
verapamil
perform
genomewid
screen
human
chronic
myelogen
leukemia
cell
line
concentr
inhibit
growth
compar
untreat
micromolar
rang
figur
use
cell
fit
phenotyp
readout
figur
initi
valid
sertralin
hit
suggest
could
detect
strong
genet
interact
genomewid
screen
cad
figur
valid
concern
whether
use
micromolar
dose
cancer
cell
line
cell
fit
readout
give
insight
vivo
biolog
drug
cad
indic
cancer
howev
previou
demonstr
success
approach
bisphosphon
suggest
might
yield
meaning
result
cad
well
comparison
six
cad
screen
vs
genomescal
screen
oppos
target
screen
eg
involv
kinom
other
perform
noncad
show
specif
cad
signatur
figur
nineteen
gene
score
averag
absolut
valu
least
standard
deviat
away
mean
six
cad
screen
hereaft
refer
pool
varianc
pv
figur
tabl
said
anoth
way
pv
aggreg
phenotyp
strengtheffect
size
gene
knockdown
cad
test
vast
major
top
hit
endoplasm
reticulum
er
golgi
local
factor
includ
regul
sphingolipid
metabol
subunit
conserv
oligomer
golgi
cog
golgiassoci
retrograd
protein
garp
complex
initi
enzym
sphingolipid
biosynthesi
serin
palmitoyltransferas
spt
long
chain
base
subunit
top
overal
gene
hit
score
pv
collagen
type
iv
protein
pv
also
known
ceramid
transfer
protein
cert
starrel
lipid
transfer
protein
th
best
hit
regul
subunit
three
spt
serin
palmitoyltransferas
small
subunit
sptssa
pv
th
strongest
hit
three
aforement
gene
key
sphingolipid
metabol
gene
sensit
hit
mean
knock
confer
hypersensit
cell
fitnessreduc
effect
cad
valid
screen
result
use
myriocin
also
known
potent
small
molecul
spt
inhibitor
figur
use
myriocin
cad
dose
affect
cell
fit
singl
agent
consist
sign
convent
screen
indic
knockdown
strongli
sensit
cell
cad
myriocin
near
complet
synthet
lethal
interact
chloroquin
cad
test
figur
level
synthet
interact
detect
cad
inhibit
spt
reminisc
result
identifi
wellaccept
bisphosphon
mechan
action
moa
target
farnesyl
diphosph
synthas
fdp
top
hit
evalu
multipl
bisphosphon
result
therefor
suggest
inhibit
spt
might
import
moa
divers
cad
overlap
hit
genomewid
screen
pathogen
cad
vs
noncad
consid
top
score
gene
chloroquin
larg
indistinguish
cad
chloroquin
appear
effect
differ
type
pathogen
name
parasit
virus
wonder
genomescal
screen
involv
pathogen
would
overlap
best
cad
last
decad
numer
genomescal
screen
identifi
host
factor
respons
toxic
effect
pathogen
includ
ebola
adenoassoci
hiv
rotaviru
influenza
zika
viru
picornaviru
exotoxin
cholera
toxin
type
iii
secret
system
shiga
toxin
ricin
toxin
toxoplasma
gondii
analyz
screen
count
number
pathogen
human
gene
score
statist
signific
gene
number
pathogen
screen
hit
stratifi
base
rank
within
screen
analysi
identifi
sphingolipid
metabol
factor
includ
cofactor
sptssa
cog
garp
complex
nine
top
ten
overal
hit
figur
moreov
hit
specif
cad
larg
nt
score
noncad
overlap
top
pathogen
cad
screen
hit
figur
taken
togeth
result
suggest
cad
gener
would
expect
strongli
modul
toxic
effect
divers
pathogen
vitro
pathogen
damag
vesicl
get
target
autophagi
defend
cell
pathogen
notabl
sphingolipid
metabol
cog
garp
complex
relat
regul
step
autophagi
autophagosom
format
consist
cad
regul
cleavag
key
initi
event
autophagi
much
strongli
noncad
figur
cog
garp
regul
sphingolipid
metabol
viral
pathogen
via
autophagi
suggest
one
potenti
import
way
cad
may
modul
pathogen
toxic
via
effect
host
cell
autophagi
gain
addit
mechanist
insight
common
effect
divers
cad
perform
transcriptom
analysi
cad
noncad
identifi
sever
noncel
autonom
process
extravas
fibrinolysi
top
gene
ontolog
categori
enrich
across
six
cad
tabl
extravas
case
immun
cell
refer
movement
circulatori
system
toward
site
tissu
damag
infect
fibrinolysi
process
prevent
blood
clot
grow
gene
enrich
seem
interest
us
like
sphingolipid
cog
garp
complex
intracellularli
fibrinolysi
extravas
molecularli
link
extracellularli
among
fibrinolysi
hit
serin
proteas
inhibitor
serpin
famili
e
member
activ
express
show
largest
foldchang
vs
control
averag
increas
across
six
cad
figur
inhibit
tissu
plasminogen
activ
tpa
key
gener
plasmin
drive
fibrinolysi
figur
result
suggest
cad
put
inhibit
fibrinolysi
via
seem
gener
counterintuit
therapeut
perspect
nevertheless
got
attent
prognosi
associ
elev
ddimer
result
plasmin
cleavag
figur
plasmin
also
got
attent
cleav
spike
protein
relat
viru
facilit
entri
via
host
receptor
angiotensinconvert
enzym
host
receptor
figur
potenti
broader
role
pathogen
support
plasmin
cleav
pathogen
protein
hemagglutinin
influenza
viru
increas
virul
valid
express
specif
elev
cad
noncad
determin
elev
dose
depend
figur
e
reciproc
relationship
sphingolipid
autophagi
regul
sphingolipid
metabol
autophagi
regul
therefor
potenti
relat
regul
host
respons
autophagi
result
suggest
cad
sphingolipid
might
influenc
pathogen
virul
via
result
import
light
novel
coronaviru
cad
test
alreadi
fda
approv
one
cad
screen
amiodaron
shown
efficaci
vitro
anoth
cad
screen
verapamil
recent
identifi
gordon
et
al
use
proteom
analysi
possibl
relev
yet
peer
review
suggest
amongst
drug
gordon
et
al
discov
verapamil
might
potenti
priorit
preclin
investig
lastli
azithromycin
shown
promis
combin
chloroquin
interest
consid
azithromycin
pka
clogp
abil
promot
phospholipidosi
vivo
suggest
might
also
act
cad
context
patient
respond
well
chloroquin
wherea
other
pandem
continu
import
better
understand
respond
treatment
establish
genomewid
screen
cell
identifi
key
genet
determin
predict
bad
outcom
take
bisphosphon
similar
cellular
analysi
treatment
consid
soon
clear
frontrunn
addit
work
suggest
cad
could
consid
preclin
investig
pathogen
includ
yettoemerg
effect
therapi
vaccin
inde
mani
cad
includ
studi
tamoxifen
increasingli
note
inhibitori
effect
variou
infecti
agent
even
vivo
knowledg
first
metaanalysi
genomewid
screen
human
cell
identifi
consensu
host
factor
import
human
pathogen
genomewid
screen
human
cell
pathogen
focus
poorli
character
gene
rather
potenti
univers
import
one
identifi
univers
host
factor
sphingolipid
metabol
cog
garp
complex
import
light
recent
put
forth
omnigen
model
model
state
gene
contribut
human
diseas
though
core
gene
contribut
nt
clear
understand
might
core
gene
diseas
work
suggest
sphingolipid
metabol
cog
garp
complex
repres
potenti
core
host
respons
gene
divers
human
pathogen
sever
potenti
reason
relat
membran
biolog
may
explain
cad
sphingolipid
particularli
import
host
respons
pathogen
sphingolipid
key
part
lipid
raft
common
point
entri
mani
pathogen
exampl
requir
sphingolipid
lipid
raft
bind
insid
cell
pathogen
also
suscept
uniqu
chemic
properti
sphingolipid
cad
exampl
ceramid
nonswel
amphiphil
impli
give
rise
micel
aggreg
though
understudi
would
seem
modul
membran
inclus
bodi
use
mani
pathogen
evad
destruct
also
pathogen
need
er
make
consid
cad
associ
membran
potenti
er
could
explain
cad
effect
type
pathogen
cad
potenti
effect
mani
antipathogen
drug
exampl
zinc
antivir
use
combin
therapi
intern
zinc
ion
larg
limit
incompat
cell
membran
chemistri
chloroquin
zinc
ionophor
increas
zinc
uptak
cell
therebi
promot
biolog
effect
sever
limit
analysi
like
chloroquin
myriocin
immunosuppress
suggest
myriocin
eventu
becom
consid
treatment
pathogen
might
make
patient
situat
wors
consist
preclin
studi
myriocin
shown
promot
host
infect
herp
simplex
dengu
virus
compar
genomewid
mutagenesi
screen
cell
fit
use
phenotyp
acknowledg
reporterbas
screen
yield
import
inform
might
miss
howev
use
cell
fit
robust
importantli
enabl
us
make
applestoappl
comparison
screen
critic
compar
screen
use
differ
mutagenesi
strategi
crispr
crispri
haploid
rnai
differ
type
perturb
small
molecul
pathogen
done
result
suggest
cad
inhibit
spt
therebi
inhibit
sphingolipid
biosynthesi
ceramid
product
previou
studi
antidepress
demonstr
cad
act
sphingolipid
catabol
particular
acid
sphingomyelinas
also
gener
ceramid
rule
cad
decreas
ceramid
level
level
anabol
catabol
process
howev
screen
strongli
suggest
former
prion
type
pathogen
includ
analysi
genomewid
screen
human
cell
yet
done
one
consid
prion
misfold
pathogen
protein
amyloid
tau
also
engag
autophagi
hypothes
sphingolipid
biosynthesi
cog
garp
complex
would
also
score
strongli
genomewid
screen
protein
grow
evid
infecti
agent
might
import
caus
factor
alzheim
diseas
ad
infecti
agent
misfold
protein
definit
pathogen
futur
interest
assess
cad
effect
interrel
type
pathogen
develop
ad
neurodegen
condit
figur
genomewid
screen
human
cell
reveal
inhibit
serin
palmitoyltransferas
potenti
mechan
action
divers
cad
chemic
structur
properti
sever
fdaapprov
cation
amphipath
drug
cad
noncad
follow
cad
sertralin
nortriptylin
fluoxetin
verapamil
amiodaron
chloroquin
noncad
alendron
metformin
atorvastatin
shown
cad
rel
high
partit
coeffici
clogp
acid
dissoci
constant
pka
clogp
rel
hydrophob
pka
valu
weakli
basic
b
schemat
genomewid
screen
process
mutagenesi
approach
use
crispr
interfer
crispri
use
cad
concentr
drug
refer
concentr
drug
inhibit
cell
fit
rel
untreat
cell
c
metaanalysi
cad
screen
mutagenesi
type
h
refer
haploid
genetrap
mutagenesi
type
refer
crispri
refer
biolog
replic
previous
publish
pool
varianc
pv
absolut
valu
aggreg
phenotyp
strengtheffect
size
gene
knockdown
cad
test
pvalu
individu
screen
combin
fdradjust
multipl
comparison
human
gene
analyz
though
gene
plot
valu
log
nt
exist
drug
concentr
cad
use
crispri
screen
follow
fluoxetin
nortriptylin
chloroquin
verapamil
amiodaron
sertralin
individu
screen
result
provid
tabl
score
cad
top
hit
cad
noncad
screen
comparison
phenotyp
score
gene
pv
six
cad
test
vs
pv
noncad
alendron
lovastatin
simvastatin
phenformin
hht
imatinib
ponatinib
zoledron
dot
line
reflect
threshold
pv
fdradjust
pvalu
six
screen
individu
pvalu
e
initi
step
sphingolipid
biosynthesi
pathway
design
synthet
interact
experi
involv
combin
myriocin
cad
serin
palmitoyltransferas
known
site
action
myriocin
hypothes
site
action
cad
f
synthet
interact
test
spt
cad
synthet
interact
strength
spt
cad
test
myriocin
inhibit
three
spt
noncad
cad
dose
use
minim
inhibit
cell
fit
base
data
figur
dose
use
follow
noncad
alendron
phenformin
cad
amiodaron
verapamil
chloroquin
sertralin
pvalu
twoway
anova
control
vs
experiment
sampl
compar
singl
agent
myriocin
cad
vs
combin
myriocin
cad
detail
inform
statist
test
exact
pvalu
comparison
provid
tabl
copyright
holder
preprint
peerreview
hour
treatment
mrna
level
assess
rtqpcr
pvalu
anova
control
vs
experiment
sampl
oneway
twoway
anova
perform
mrna
express
atp
analysi
respect
detail
inform
statist
test
exact
pvalu
comparison
provid
tabl
tabl
data
relat
figur
follow
tabl
relat
figur
figur
includ
tabl
genomewid
screen
result
work
chemic
properti
inform
cad
noncad
detail
previous
publish
genomewid
small
molecul
screen
includ
analysi
statist
analysi
perform
figur
includ
exact
pvalu
figur
phenotyp
noncad
cad
overlap
pathogen
cad
screen
hit
determin
assess
mani
top
pathogen
screen
hit
score
pv
least
two
cad
one
visual
figur
heatmap
gene
met
criteria
tabl
detail
pathogen
genomewid
screen
analyz
enrichrdetermin
gene
ontolog
categori
gene
identifi
commonli
score
across
pathogen
screen
tabl
e
dose
depend
express
cad
noncad
cell
treat
pvalu
unpair
ttest
correct
multipl
comparison
holmsidak
method
compar
untreat
vs
cad
dose
detail
inform
statist
test
exact
pvalu
comparison
provid
tabl
tabl
data
relat
figur
follow
tabl
relat
figur
includ
tabl
full
rnaseq
data
cad
noncad
enrichrdetermin
gene
ontolog
provid
gene
enrich
cad
statist
analysi
perform
figur
includ
exact
pvalu
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
penicillinstreptomycin
cell
line
cultur
medium
glutamax
supplement
fb
penicillinstreptomycin
cell
line
maintain
genomescal
screen
genomescal
screen
carri
similar
previous
publish
screen
crispri
sgrna
librari
transduc
crispricompet
cell
low
moi
two
day
transduct
infect
cell
select
ugml
puromycin
three
day
transduct
confirm
flow
cytometri
cell
recov
puromycin
select
two
day
two
day
recoveri
initi
sampl
cell
million
frozen
remain
cell
million
cell
split
either
untreat
c
treat
drug
interest
flask
untreat
treat
group
cell
kept
million
cellsml
daili
drug
treatment
continu
untreat
cell
doubl
five
eight
time
treat
cell
cell
recov
week
allow
treat
cell
undergo
three
four
doubl
genom
dna
isol
librari
prepar
perform
previous
describ
genomescal
gene
trap
screen
use
haploid
cell
perform
previous
describ
brief
genet
select
indic
small
molecul
drug
perform
million
mutagen
cell
cell
expos
drug
allow
recov
sever
week
averag
week
harvest
surviv
cell
isol
genom
dna
analysi
screen
follow
sequenc
flank
retrovir
insert
site
determin
use
invers
pcr
follow
illumina
sequenc
map
sequenc
human
genom
count
number
inactiv
mutat
mutat
sens
orient
present
exon
per
individu
refseqannot
gene
well
total
number
inactiv
insert
refseqannot
gene
gene
statist
enrich
calcul
compar
often
gene
mutat
drugtreat
popul
often
gene
carri
insert
untreat
control
dataset
gene
pvalu
correct
fals
discoveri
rate
calcul
use
onesid
fisher
exact
test
individu
valid
sgrna
phenotyp
sgrna
protospac
target
indic
gene
control
protospac
target
egfp
nontarget
colloqui
refer
control
respect
individu
clone
anneal
complementari
synthet
oligonucleotid
pair
integr
dna
technolog
flank
bstxi
blpi
restrict
site
ligat
result
doublestrand
segment
bstxiblpidigest
mark
puromycin
resist
cassett
bfp
addgen
protospac
sequenc
use
individu
evalu
list
result
sgrna
express
vector
individu
packag
lentiviru
intern
control
growth
assay
evalu
sgrna
drug
sensit
phenotyp
perform
transduc
cell
sgrna
express
construct
moi
infect
cell
select
puriti
puromycin
allow
recov
least
day
treat
cell
indic
concentr
drug
dmso
day
infect
measur
fraction
sgrnaexpress
cell
hour
process
popul
cell
harvest
measur
mrna
level
rtqpcr
see
experi
perform
triplic
treatment
step
knockdown
gene
perform
batch
control
sgrna
cell
data
control
cell
averag
allow
comparison
gene
scale
crispri
sgrna
sequenc
obtain
aforement
librari
select
two
avail
sgrna
base
one
score
best
screen
human
individu
gene
analysi
total
rna
isol
reversetranscript
perform
cell
tissu
indic
condit
result
cdna
dilut
dnasefre
water
follow
quantif
realtim
pcr
mrna
transcript
measur
use
appli
biosystem
sequenc
detect
system
softwar
data
express
ratio
express
target
gene
housekeep
gene
actb
actin
andor
gapdh
treat
sampl
normal
control
cell
type
human
pcr
primer
sequenc
obtain
http
pgamghharvardeduprimerbank
rnaseq
experi
total
rna
prepar
cell
analyz
use
standard
pipelin
cell
fit
assay
wildtyp
mutant
cell
seed
cell
per
well
tissu
cultur
plate
treat
indic
concentr
compound
left
untreat
hour
treatment
cell
viabil
measur
use
celltit
glo
colorimetr
assay
promega
accord
manufactur
protocol
fit
plot
percentag
compar
untreat
control
growth
inhibitori
inhibitori
concentr
use
latter
refer
inhibit
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
maxim
inhibit
maximum
inhibit
vari
drug
therefor
use
instead
allow
us
compar
drug
scale
protein
analysi
cell
rins
twice
icecold
pb
lyse
cell
lysi
buffer
cell
signal
proteas
phosphatas
inhibitor
cocktail
thermofish
scientif
ad
lysat
incub
centigrad
constant
invers
solubl
fraction
cell
lysat
isol
centrifug
rpm
min
microcentrifug
lysat
protein
concentr
normal
bradford
assay
biorad
protein
denatur
addit
sampl
buffer
boil
minut
resolv
use
sdspage
invitrogen
analyz
immunoblot
indic
protein
immunoblot
perform
follow
nitrocellulos
membran
block
room
temperatur
rt
bsa
membran
incub
overnight
c
indic
primari
antibodi
dissolv
bsa
membran
wash
time
tbst
wash
last
membran
incub
rt
desir
secondari
antibodi
milk
hrpconjug
fluoresc
secondari
antibodi
santa
cruz
biotechnolog
thermo
fisher
respect
use
detect
membran
wash
time
tbst
wash
last
signal
membran
use
hrpconjug
secondari
antibodi
captur
use
camera
use
fluoresc
secondari
antibodi
imag
ge
typhoon
trio
imag
cheminformat
bioinformat
analysi
chemic
properti
cad
noncad
obtain
pubchem
http
pubchemncbinlmnihgov
drugbank
http
wwwdrugbankca
pubchem
incomplet
addit
chemic
properti
present
tabl
calcul
use
advanc
chemistri
develop
acdlab
softwar
imag
chemic
structur
obtain
wikipedia
chemic
differ
noncad
bisphosphon
biguanid
statin
use
throughout
work
follow
bisphosphon
alendron
differ
zoledron
acid
zoledron
r
group
biguanid
phenformin
use
throughout
work
differ
metformin
phenyl
ring
unlik
vivo
phenformin
metformin
regul
metabol
consist
expect
moa
biguanid
vitro
phenformin
activ
put
relev
concentr
reason
poor
metformin
efficaci
vitro
nt
well
understood
statin
statin
use
work
atorvastatin
lovastatin
simvastatin
rel
lipophil
compar
hydrophil
statin
rosuvastatin
simvastatin
close
structur
relat
lovastatin
atorvastatin
amongst
previous
publish
small
molecul
pathogen
screen
gene
loss
function
ie
haploid
genetrap
crispr
rnai
gainoffunct
screen
ie
crispra
retrovir
overexpress
consid
analysi
multipl
mutagenesi
strategi
compar
ensur
gene
consid
hit
nt
found
one
method
screen
without
readili
appar
mean
separ
signific
gene
hit
vs
nonsignific
gene
consid
rational
choos
noncad
analyz
follow
rigosertib
hht
knowledg
noncad
analyz
use
crispri
cell
mutagenesi
strategi
cell
type
use
cad
ponatinib
imatinib
noncad
screen
cell
one
common
cell
type
analyz
see
tabl
commonli
use
research
commun
identifi
host
factor
pathogen
exampl
screen
pathogen
small
molecul
screen
analyz
includ
ebola
pathogen
pmid
unabl
understand
report
statist
signific
cutoff
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
gene
ontolog
analysi
perform
use
enrichr
http
amppharmmssmeduenrichr
gene
interest
input
enrichr
output
taken
ontolog
go
biolog
process
similar
result
obtain
use
gene
ontolog
web
servic
http
geneontologyorg
though
servic
algorithm
priorit
larger
cluster
gene
calcul
signific
hit
figur
crispri
analysi
gene
input
enrichr
increas
treatment
rel
dmso
vehicl
control
figur
gene
express
analysi
gene
input
enrichr
increas
treatment
rel
dmso
vehicl
control
dmso
count
per
million
cpm
greater
statist
graphic
analysi
unless
otherwis
specifi
group
compar
analysi
varianc
anova
correct
multipl
comparison
tukey
method
use
graphpad
prism
version
softwar
data
express
mean
sd
graphpad
prism
also
use
gener
graph
except
figur
rstudio
use
code
avail
via
git
repositori
http
githubcomtimpetersoncadspathogen
doi
combin
pvalu
individu
screen
done
figur
fals
discoveri
rate
fdr
also
known
benjamini
hochberg
method
adjust
pvalu
use
python
code
use
import
librari
omit
clariti
code
invok
avail
via
cadspathogen
git
repositori
sptssa
ugcg
kdsr
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
